157 related articles for article (PubMed ID: 30781409)
1. 2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction,
Maier FC; Schweifer A; Damaraju VL; Cass CE; Bowden GD; Ehrlichmann W; Kneilling M; Pichler BJ; Hammerschmidt F; Reischl G
Pharmaceuticals (Basel); 2019 Feb; 12(1):. PubMed ID: 30781409
[TBL] [Abstract][Full Text] [Related]
2. [
Schweifer A; Maier F; Ehrlichmann W; Lamparter D; Kneilling M; Pichler BJ; Hammerschmidt F; Reischl G
Nucl Med Biol; 2016 Dec; 43(12):759-769. PubMed ID: 27693670
[TBL] [Abstract][Full Text] [Related]
3. β -[
Kumar P; Roselt P; Reischl G; Cullinane C; Beiki D; Ehrlichmann W; Binns D; Naimi E; Yang J; Hicks R; Machulla HJ; Wiebe LI
Curr Radiopharm; 2017; 10(2):93-101. PubMed ID: 28294075
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three
Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[
Wanek T; Kreis K; Križková P; Schweifer A; Denk C; Stanek J; Mairinger S; Filip T; Sauberer M; Edelhofer P; Traxl A; Muchitsch VE; Mereiter K; Hammerschmidt F; Cass CE; Damaraju VL; Langer O; Kuntner C
Bioorg Med Chem; 2016 Nov; 24(21):5326-5339. PubMed ID: 27614920
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and hypoxia selective radiosensitization potential of beta-2-FAZA and beta-3-FAZL: fluorinated azomycin beta-nucleosides.
Kumar P; Emami S; Kresolek Z; Yang J; McEwan AJ; Wiebe LI
Med Chem; 2009 Mar; 5(2):118-29. PubMed ID: 19275710
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
[TBL] [Abstract][Full Text] [Related]
8. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
Reischl G; Dorow DS; Cullinane C; Katsifis A; Roselt P; Binns D; Hicks RJ
J Pharm Pharm Sci; 2007; 10(2):203-11. PubMed ID: 17706178
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, transportability and hypoxiaselective binding of 1-beta-D-(5-Deoxy-5-fluororibofuranosyl)-2-nitroimidazole (beta-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA.
Emami S; Kumar P; Yang J; Kresolic Z; Paproski R; Cass C; McEwan AJ; Wiebe LI
J Pharm Pharm Sci; 2007; 10(2):237-45. PubMed ID: 17706182
[TBL] [Abstract][Full Text] [Related]
10. First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer.
Thureau S; Piton N; Gouel P; Modzelewski R; Dujon A; Baste JM; Melki J; Rinieri P; Peillon C; Rastelli O; Lequesne J; Hapdey S; Sabourin JC; Bohn P; Vera P
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439254
[TBL] [Abstract][Full Text] [Related]
11. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.
Zanzonico P; O'Donoghue J; Chapman JD; Schneider R; Cai S; Larson S; Wen B; Chen Y; Finn R; Ruan S; Gerweck L; Humm J; Ling C
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):117-28. PubMed ID: 14523586
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
Peeters SG; Zegers CM; Lieuwes NG; van Elmpt W; Eriksson J; van Dongen GA; Dubois L; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):351-9. PubMed ID: 25491505
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of hypoxia imaging agent 1-(5-deoxy-5-fluoro-α-D-arabinofuranosyl)-2-nitroimidazole using microfluidic technology.
Bouvet VR; Wuest M; Wiebe LI; Wuest F
Nucl Med Biol; 2011 Feb; 38(2):235-45. PubMed ID: 21315279
[TBL] [Abstract][Full Text] [Related]
14. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors.
Sorger D; Patt M; Kumar P; Wiebe LI; Barthel H; Seese A; Dannenberg C; Tannapfel A; Kluge R; Sabri O
Nucl Med Biol; 2003 Apr; 30(3):317-26. PubMed ID: 12745023
[TBL] [Abstract][Full Text] [Related]
15. Kinetic Evaluation of the Hypoxia Radiotracers [
Choen S; Kent MS; Chaudhari AJ; Cherry SR; Krtolica A; Zwingenberger AL
Nucl Med Mol Imaging; 2023 Feb; 57(1):16-25. PubMed ID: 36643946
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of [
Sun W; Falzon C; Naimi E; Akbari A; Wiebe LI; Tandon M; Kumar P
Curr Radiopharm; 2019; 12(1):49-57. PubMed ID: 30338747
[TBL] [Abstract][Full Text] [Related]
17. First Evaluation of PET-Based Human Biodistribution and Dosimetry of
Savi A; Incerti E; Fallanca F; Bettinardi V; Rossetti F; Monterisi C; Compierchio A; Negri G; Zannini P; Gianolli L; Picchio M
J Nucl Med; 2017 Aug; 58(8):1224-1229. PubMed ID: 28209906
[No Abstract] [Full Text] [Related]
18. Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging.
Zha Z; Zhu L; Liu Y; Du F; Gan H; Qiao J; Kung HF
Nucl Med Biol; 2011 May; 38(4):501-8. PubMed ID: 21531287
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
